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ABSTRACT
Introduction: Pitavastatin is a novel, potent, 
3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitor. This study compared the 
long-term efficacy of pitavastatin and simvastatin 
in dyslipidemic patients at high risk of coronary 
heart disease. Methods: A 44-week blinded 
extension study was conducted at 24 centers in 
five European countries for patients who had 
previously completed a 12-week randomized, 
double-blind core study in which they received 
pitavastatin 4 mg or simvastatin 40 mg once daily. 
Patients originally randomized to pitavastatin 
4 mg continued at the same dose throughout the 
extension study (n=121). In simvastatin-treated 
patients (n=57), the dose was increased to 80 mg 
in five patients who had not attained the National 
Cholesterol Education Program (NCEP) target 
for low-density lipoprotein cholesterol (LDL-C) 
during the core study. Primary endpoints were the 
proportion of patients attaining the NCEP and 
European Atherosclerosis Society (EAS) LDL-C 
targets, and the NCEP target for non-high-density 
lipoprotein cholesterol (non-HDL-C) at weeks 16 
and 44. Results: Of the 178 patients who entered 
the extension study, 156 patients (109 in the 
pitavastatin group, 47 in the simvastatin groups) 
completed the 44-week treatment period. At week 
44, NCEP and EAS targets were attained by 81.7% 
and 84.2%, respectively, of pitavastatin-treated 
patients, and 75.4% and 73.7%, respectively, 
of simvastatin-treated patients. NCEP targets 
for non-HDL-C were achieved by 79.2% of 
pitavastatin-treated patients and 70.2% of 
simvastatin-treated patients. Both treatments 
were generally well tolerated, but pitavastatin 
4 mg was associated with a numerically lower 
incidence of discontinuations due to treatment-
emergent adverse events (5.8% vs. 10.5% of 
patients) and a lower rate of myalgia (4.1% vs. 
12.3%) compared with simvastatin 40-80 mg. 
Conclusion: Pitavastatin 4 mg provides long-term 
efficacy similar to that of simvastatin 40-80 mg. 
Further studies should ascertain whether trends 
suggesting that pitavastatin may exhibit a more 
favorable long-term tolerability profile are 
statistically significant.
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INTRODUCTION
Elevated serum cholesterol concentrations, 
particularly low-density lipoprotein cholesterol 
(LDL-C), is a recognized risk factor for 
coronary heart disease (CHD), and numerous 
interventional studies have shown that lowering 
LDL-C delays the progression of atherosclerotic 
lesions and reduces cardiovascular mortality and 
morbidity associated with CHD.1 As a result, 
current guidelines for the prevention of CHD 
recommend the use of lipid-modifying therapy 
in patients with dyslipidemia.2,3 3-Hydroxy-
3-methylglutaryl coenzyme A reductase 
inhibitors (statins) have become the most widely 
used lipid-modifying agents, due to their proven 
efficacy in lowering total cholesterol and LDL-C 
concentrations and beneficial effects on other 
lipid fractions, such as high-density lipoprotein 
cholesterol (HDL-C) and triglycerides.1,4
However, several observational studies 
have shown that a significant proportion of 
patients do not attain recommended LDL-C 
concentration targets despite treatment with 
statins.5-8 Such findings highlight the need for 
more effective lipid-lowering strategies, which 
could include the use of more aggressive initial 
therapy, more potent agents, dose adjustment 
during treatment, or combination therapy using 
agents with different mechanisms of action.
Pitavastatin is a novel, highly potent statin 
that has been shown to provide significant 
reductions in total cholesterol, LDL-C, and 
triglyceride concentrations in patients with 
hyperlipidemia9 or heterozygous familial 
hypercholesterolemia.10,11 Pitavastatin has also 
been shown to produce sustained increases 
in HDL-C concentrations over 52 weeks.12 
Unlike other statins, pitavastatin does not 
undergo extensive metabolism by cytochrome 
P450 isoenzymes, and hence the potential for 
interactions with drugs that are metabolized by 
cytochrome P450 is low.12,13
A 12-week, randomized, double-blind trial 
in patients at high risk of CHD showed that 
pitavastatin 4 mg was statistically non-inferior 
to simvastatin 40 mg for the reduction of LDL-C 
concentrations, and provided larger increases in 
HDL-C (6.8% vs. 4.5%; P=0.083) and reductions 
in triglycerides (–19.8% vs. –14.8%; P=0.044) 
than simvastatin treatment.14 We report the 
results of a 44-week extension study designed 
to compare the long-term safety and efficacy of 
pitavastatin 4 mg and simvastatin 40-80 mg. The 
primary endpoint was the proportion of patients 
attaining the LDL-C targets recommended by 
the National Cholesterol Education Program 
(NCEP)2 and the European Atherosclerosis 
Society (EAS).3 Secondary objectives were to 
assess the efficacy of the two statins on other 




The inclusion and exclusion criteria of the 
study have been described in detail previously.14
In brief, patients aged 18-75 years were 
eligible if they had uncontrolled primary 
hypercholesterolemia or combined dyslipidemia 
(LDL-C concentrations of ≥3.4 mmol/L 
[130 mg/dL] and ≤5.7 mmol/L [220 mg/dL]; 
triglycerides ≤4.6 mmol/L [400 mg/dL]) and 
at least two other risk factors for CHD. The 
principal exclusion criteria were homozygous 
familial hypercholesterolemia, unstable medical 
conditions or conditions associated with 
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secondary dyslipidemia, conditions that might 
affect drug pharmacokinetics, and significant 
medical illness. Women of childbearing potential 
were required to have a negative pregnancy test 
at the start of the dietary run-in period and 
before starting treatment, and to use adequate 
contraception throughout the study.
The study was performed in compliance with 
the Declaration of Helsinki, the draft Note for 
Guidance on Clinical Investigation of Medicinal 
Products in the Treatment of Lipid Disorders 
by the Committee for Proprietary Medicinal 
Products, and the International Conference on 
Harmonization (ICH) of Technical Requirements 
for Registration of Pharmaceuticals for Human 
Use - Harmonized Tripartite Guidelines for Good 
Clinical Practice. The protocol was approved by 
local institutional review boards or independent 
ethics committees at each center. All participants 
provided written informed consent before 
inclusion in the study.
Study Design 
The study was a 44-week, double-blind, double-
dummy, parallel-group, active-controlled 
extension study in patients who had completed 
the core study. It was conducted at 24 centers 
(predominantly in lipid clinics, cardiology 
clinics, and university hospitals) in Denmark, 
the Netherlands, Spain, Sweden, and the United 
Kingdom. 
During the core study, patients were 
randomized 2:1 to receive pitavastatin 4 mg 
or simvastatin 40 mg. Randomization was 
performed using an interactive voice recognition 
system at each center. Patients entering the 
extension study were maintained on the same 
drug they had received during the core study. 
Pitavastatin-treated patients continued on the 
same dose (4 mg) throughout the extension 
study. In the simvastatin group, patients who 
had reached the NCEP LDL-C target by week 8 
of the core study were maintained at a dose of 
40 mg during the extension study, whereas in 
patients who had not reached this target the 
dose was increased to 80 mg at the start of the 
extension study. The sponsors, clinical trial 
team, and patients remained blinded to target 
achievement during the core study. Treatment 
was given once-daily in the evening, and all 
other lipid-modifying therapies were prohibited 
for the duration of the study. Compliance was 
checked by counting unused tablets or capsules 
at each study visit. Throughout the extension 
study, all patients continued to follow the same 
fat- and cholesterol-restrictive diet that they had 
followed during the core study.
During the extension study, treatment 
was administered following the double-blind 
protocol used in the core study. However, after 
16 weeks the sponsor and statisticians were 
unblinded to permit reporting of the core 
study data, while the investigators and patients 
remained blinded for the duration of the 
extension study. Treatment was given according 
to a double-dummy design. Pitavastatin 4 mg 
tablets and matching placebos were supplied 
by SkyePharma Production (Saint Quentin-
Fallavier, France). Over-encapsulated simvastatin 
tablets and matching placebos were supplied by 
Almac (Craigavon, UK). 
Blood samples for lipid analyses were 
obtained after a 12-hour fast at the start of the 
extension study (ie, after 12 weeks in the core 
study) and at weeks 4, 8, 16, 24, 32, and 44.
Outcome Measures
The primary lipid-related endpoints in the 
extension study were the proportion of patients 
attaining the LDL-C targets, as recommended 
by the NCEP and EAS, at weeks 16 and 44, and 
the proportion attaining the NCEP target for 
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non-HDL-C concentration at the same time 
points. LDL-C concentrations were calculated 
using the Friedewald formula,15 except in 
patients with triglyceride concentrations above 
4.6 mmol/L, where LDL-C was measured by 
ultracentrifugation due to the known effect of 
high triglyceride concentrations on the accuracy 
of the Friedewald formula.16 A further analysis 
was based on non-HDL-C and triglyceride 
concentrations, as described in step 9 of the NCEP 
criteria.2 The NCEP criteria provides a stepwise 
approach to determining and treating lipid-
associated risk factors for CHD. In patients who 
achieved their LDL-C targets at each visit and had 
triglyceride concentrations above 2.3 mmol/L 
(200 mg/dL), non-HDL-C targets were assigned 
that were 0.78 mmol/L (30 mg/dL) higher than 
their LDL-C target. These patients were required 
to attain both their LDL-C and non-HDL-C 
targets to achieve their step 9 target. In patients 
who did not achieve LDL-C targets, the LDL-C 
target was regarded as the step 9 target. Secondary 
lipid assessments and other secondary efficacy 
endpoints included the percentage changes 
from baseline in concentrations of LDL-C, total 
cholesterol, HDL-C, non-HDL-C, triglycerides, 
apolipoprotein B (Apo-B) and apolipoprotein A1 
(Apo-A1), and absolute changes from baseline in 
oxidized LDL levels, non-HDL-C:HDL-C ratio, 
total cholesterol:HDL-C ratio, Apo-B:Apo-A1 
ratio, and hs-CRP levels. All lipid analyses were 
performed at a central laboratory.
Safety and Tolerability
Treatment-emergent adverse events (TEAE), 
defined as any event with onset on or after 
the first dose of study drug, and serious TEAE 
were recorded throughout the study. All such 
events were coded by system organ class 
preferred term using the Medical Dictionary 
for Regulatory Activities. Clinical laboratory 
safety assessments included routine blood 
chemistry, hematology, urinalysis, liver enzymes 
(alanine aminotransferase [ALAT] and aspartate 
aminotransferase [ASAT]) and creatine kinase 
(CK). Other safety evaluations included physical 
examination, 12-lead electrocardiogram (ECG) 
and vital signs.
Statistical Analyses
No formal sample size calculation was performed 
for this extension study because the number 
of patients entering the study was dependent 
on the number completing the core study and 
agreeing to enter the extension study. It was 
anticipated that this would be approximately 
270 patients. 
Efficacy analyses were performed on the 
efficacy population, which consisted of all 
patients who received at least one dose of study 
medication and had at least one lipid assessment 
during the study. Analyses of safety data were 
performed on the safety population, which 
included all patients who received at least one 
dose of study medication. 
For the primary efficacy variables, the 
proportions of patients attaining NCEP and EAS 
LDL-C targets and NCEP non-HDL-C targets at 
weeks 16 and 44 were summarized by visit. For 
patients who withdrew before these times, the 
last available LDL-C concentration was used 
to assess whether targets had been attained. 
No formal statistical analysis was performed. 
Secondary efficacy variables were summarized 
in the same way. 
RESULTS
Patient Flow and Baseline Characteristics
The first patient was enrolled into the 
extension study on June 21 2006 and the final 
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patient visit was on August 14 2007. In total,
178 patients entered the extension study 
(Figure 1), of whom 121 had been randomized 
to receive pitavastatin during the core study and 
57 had been randomized to simvastatin. The 
dose of simvastatin was increased to 80 mg at 
the start of the extension study in five patients 
because they had not achieved the NCEP target 
for LDL-C concentrations by week 8 of the core 
study. All patients received at least one dose of 
study medication, and were therefore included 
in the safety population. One patient in the 
pitavastatin group had no lipid assessment 
during the study and was therefore excluded 
from the efficacy population; hence, the efficacy 
population consisted of 177 patients (Figure 1). 
Twenty-two patients withdrew during the study, 
mainly because of adverse events (Figure 1). 
Demographic characteristics of the patients 
entering the extension study are summarized 
in Table 1. The characteristics of the patients 
in this study were similar to those of the total 
patient population enrolled in the core study.14 
There were no clinically relevant differences 
in demographic characteristics between the 
pitavastatin and simvastatin groups.
Efficacy
Attainment of EAS and NCEP Lipid Targets
The proportions of patients achieving NCEP 
or EAS targets for LDL-C concentrations at the 
end of the extension study are summarized in 
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Figure 1. Patient disposition. *One patient excluded from the efficacy population completed the core study.
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proportion of patients meeting the NCEP or EAS 
targets was 91.5% and 94.9%, respectively, with 
pitavastatin and 90.9% and 92.7%, respectively, 
with simvastatin. At the end of the study, the 
corresponding proportions were 81.7% for 
NCEP targets and 84.2% for EAS targets with 
pitavastatin, and 75.4% and 73.7%, respectively, 
with simvastatin.
At the start of the extension study, step 9 
secondary NCEP targets (non-HDL-C or LDL-C) 
were attained by 89.8% of patients in the 
pitavastatin group, and by 87.3% of those in 
the simvastatin group (Table 3). Corresponding 
proportions at the end of the study were 79.2% 
and 70.2%, respectively.
As an additional efficacy endpoint, the 
proportion of patients achieving NCEP targets 
was analyzed according to whether or not 
patients achieved these targets during the core 
study. Of those who achieved their LDL-C 
targets during the core study, 94 of 108 patients 
(87.0%) in the pitavastatin group, and 42 of 
52 patients (80.8%) in the simvastatin group 
attained their LDL-C targets at the end of 
the extension study. Eleven patients in the 
pitavastatin group and five in the simvastatin 
group did not attain their LDL-C targets 
during the core study. Of these, three (27.3%) 
pitavastatin-treated patients and one (20.0%) 
simvastatin-treated patient attained LDL-C 
targets at the end of the extension study. The 
Table 1. Baseline demographic and clinical characteristics. 
Characteristic Pitavastatin Simvastatin 
  4 mg 40-80 mg 
  (n=121) (n=57)
White, n (%) 121 (100) 57 (100)
Gender 
 Male, n (%) 82 (67.8) 39 (68.4)
 Female, n (%) 39 (32.2) 18 (31.6)
Age (years), mean ± SD 60.4±5.8 60.8±6.5
Age group, n (%)  
  <65 years 98 (81.0) 44 (77.2)
  ≥65 years 23 (19.0) 13 (22.8)
Primary diagnosis, n (%)  
 Primary 
 hypercholesterolemia 108 (89.3) 52 (91.2)
 Combined dyslipidemia 10 (8.3) 4 (7.0)
 Heterozygous FH 3 (2.5) 1 (1.8)
Time since diagnosis (years), 
mean ± SD 2.8±4.7 3.2±4.8
Height (m), mean ± SD 1.7±0.1 1.7±0.1
Weight (kg), mean ± SD 81.3±13.1 82.4±12.7
Body mass index (kg/m2), 
mean ± SD 27.5±3.4 28.1±3.2
NCEP risk category, n (%)  
 High 28 (23.1) 19 (33.3)
 Moderate 90 (74.4) 37 (64.9)
 Low 3 (2.5) 1 (1.8)
Diabetes, n (%) 6 (5.0) 3 (5.3)
Hypertension, n (%) 68 (56.2) 36 (63.2)
FH=familial hypercholesterolemia; NCEP=National 
Cholesterol Education Program; SD=standard deviation. 
Table 2. Proportion of patients achieving National 
Cholesterol Education Program (NCEP) or European 
Atherosclerosis Society (EAS) targets for low-density 
lipoprotein cholesterol (LDL-C) during treatment with 
pitavastatin or simvastatin.
Parameter Number of patients attaining target/ 
  number of patients assessed*
  Pitavastatin, Simvastatin,  
  4 mg/day 40-80 mg/day
  (n=120) (n=57)
NCEP criteria, n/n (%)  
 Week 0 108/118 (91.5) 50/55 (90.9)
 Week 16 103/120 (85.8) 45/57 (78.9)
 Week 44 98/120 (81.7) 43/57 (75.4)
EAS criteria, n/n (%)  
 Week 0 112/118 (94.9) 51/55 (92.7)
 Week 16 105/120 (87.5) 51/57 (89.5)
 Week 44 101/120 (84.2) 42/57 (73.7)
*In patients who withdrew before week 16 or 44, 
attainment of targets was assessed using the last available 
lipid determination.
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proportion of patients meeting NCEP step 9 
targets was 84.3% with pitavastatin and 75.0% 
with simvastatin among those who attained 
their targets during the core study, and 27.3% 
and 20.0%, respectively, among those who did 
not.
Secondary Efficacy Variables
Mean changes in secondary lipid variables and 
hs-CRP levels from baseline (start of the core 
study) to week 44 are summarized in Table 4. 
In general, both treatments produced similar 
changes in these secondary measures. Although 
at week 16, HDL-C increased by 12.4% with 
pitavastatin and by 7.3% with simvastatin, 
the final increase was similar. Triglyceride 
concentrations decreased by approximately 
12%, compared with baseline, whereas the 
corresponding reductions at the end of the core 
study were approximately 20% with pitavastatin 
and 15% with simvastatin.14 Apo-B:Apo-A1 
and non-HDL-C:HDL-C ratios showed large 
decreases from baseline with both treatments, 
and only slight increases compared with the 
end of the core treatment period. Values for the 
total cholesterol:HDL-C ratio were the same as 
those for the non-HDL-C:HDL-C ratio. Apo-A1 
levels increased during the extension study in 
the simvastatin group, but remained constant in 
the pitavastatin group. 
Safety and Tolerability
TEAE
TEAE were reported by 92 patients (76.0%) 
in the pitavastatin group and by 45 patients 
(78.9%) in the simvastatin group (Table 5). The 
most common adverse events occurring during 
the extension study were nasopharyngitis, 
headache, back pain, and myalgia; most 
TEAE were mild or moderate in severity. The 
proportion of patients with TEAE considered 
to be related to study treatment was 17.5% 
with simvastatin and 10.7% with pitavastatin; 
the proportions of patients discontinuing 
treatment due to a TEAE were 10.5% and 
5.8%, respectively. The most common TEAE 
leading to withdrawal were gastrointestinal 
disorders, which occurred in three patients in 
the simvastatin group and in one patient in the 
pitavastatin group. Myalgia was reported in a 
higher proportion of patients in the simvastatin 
group (12.3%) than the pitavastatin group 
(4.1%); one patient in the simvastatin group 
discontinued treatment during the extension 
study because of myositis.
Five serious TEAE (cataract, bronchitis, 
non-cardiac chest pain, postcholecystectomy 
syndrome, and fatal myocardial ischemia) 
occurred in four (3.3%) patients in the 
pitavastatin group, and seven serious TEAE 
(myocardial infarction, global amnesia, urinary 
bladder polyps, angina pectoris, gastroenteritis, 
Table 3. Proportion of patients achieving National 
Cholesterol Education Program (NCEP) step 9* targets 
during treatment with pitavastatin or simvastatin. 
Week† Number of patients attaining target/ 
 number of patients assessed
 Pitavastatin Simvastatin 
 4 mg 40-80 mg 
 (n=120) (n=57)
Week 0, n/n (%) 106/118 (89.8) 48/55 (87.3)
Week 16, n/n (%) 99/120 (82.5) 41/57 (71.9)
Week 44, n/n (%) 95/120 (79.2) 40/57 (70.2)
*Patients who achieved their low-density lipoprotein 
cholesterol (LDL-C) targets at each visit and had serum 
triglyceride concentrations above 2.26 mmol/L (200 mg/dL) 
were required to attain both their LDL-C and non-high-
density lipoprotein cholesterol (non-HDL-C) targets to 
achieve their NCEP step 9 target. In the remaining patients, 
the LDL-C target was regarded as the NCEP step 9 target.
†In patients who withdrew before week 16 or 44, 
attainment of targets was assessed using the last available 
lipid determination.
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Table 4. Changes in secondary lipid variables and high sensitivity C-reactive protein (hs-CRP) from baseline (start of the 
core study) to the start of the extension study (week 0) and from baseline to week 44 of the extension study in patients 
treated with pitavastatin or simvastatin. 
Parameter Change from baseline (mean±SD)
  Pitavastatin 4 mg (n=120) Simvastatin 40-80 mg (n=57)
Total cholesterol
 Baseline mean (mmol/L)  6.33±0.66 6.47±0.75
 Baseline to extension week 0 (%) −33.0±6.6 −35.4±8.5
 Baseline to extension week 44 (%) −27.4±11.8 −27.4±12.0
LDL-C
 Baseline mean (mmol/L)  4.27±0.53 4.38±0.60
 Baseline to extension week 0 (%)  –46.30±9.0 –49.54±10.8
 Baseline to extension week 44 (%) –41.81±15.1 –41.37±16.4
HDL-C 
 Baseline mean (mg/dL) 1.21±0.27 1.18±0.20
 Baseline to extension week 0 (%) 9.3±13.1 7.0±10.8
 Baseline to extension week 44 (%) 14.1±17.3 14.6±16.4
Non-HDL-C  
 Baseline mean (mmol/L) 5.12±0.66 5.29±0.73
 Baseline to extension week 0 (%) −43.1±7.8 −44.8±9.9
 Baseline to extension week 44 (%) −37.2±14.2 −36.8±15.6
Non-HDL-C:HDL-C ratio (%)  
 Baseline mean 4.5±1.2 4.6±1.1
 Baseline to extension week 0 (%) −2.1±0.9 −2.2±0.8
 Baseline to extension week 44 (%) −1.9±1.8 −2.0±1.1
Total cholesterol: HDL-C ratio (%)
 Baseline mean 5.5±1.2 5.6±1.1
 Baseline to extension week 0 (%) –2.1±0.9 –2.2±0.8
 Baseline to extension week 44 (%) –1.9±1.8 –2.0±1.1
Triglycerides  
 Baseline mean (mmol/L) 1.86±0.81 1.99±0.84
 Baseline to extension week 0 (%) −24.4±18.9 −22.6±20.3
 Baseline to extension week 44 (%) −11.5±42.7 −12.3±22.7
Apo-B  
 Baseline mean (mg/dL) 151.7±21.8 156.0±22.4
 Baseline to extension week 0 (%) −35.3±9.7 −37.5±10.7
 Baseline to extension week 44 (%) −35.1±13.3 −34.7±12.0
Apo-A1  
 Baseline mean (mg/dL) 159.6±26.4 158.4±20.4
 Baseline to extension week 0 (%) 7.7±13.3 7.5±12.0
 Baseline to extension week 44 (%) 7.2±15.7 10.7±13.5
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bladder cancer, and transient ischemic attack) 
occurred in seven patients (12.3%) in the 
simvastatin group. None of these adverse events 
was considered to be treatment related.
Laboratory Abnormalities
Long-term treatment with pitavastatin 4 mg 
was associated with a very low incidence of 
notable elevations of either liver enzymes (ASAT 
or ALAT) or CK. One patient in the pitavastatin 
group showed a single instance of elevations of 
ASAT and ALAT to above five times the upper 
limit of normal (ULN). There were isolated cases 
of CK elevations above three or five times the 
ULN in the pitavastatin-treated group, but no 
cases where such elevations were reported on 
two consecutive visits. No clinically relevant 
findings were observed on urinalysis, physical 
examination, vital signs, or ECG.
DISCUSSION
This 44-week extension study has shown that 
long-term treatment with pitavastatin 4 mg 
provides similar efficacy to simvastatin 40-80 mg 
and may have a more favorable tolerability profile 
in patients with primary hypercholesterolemia 
or combined (mixed) dyslipidemia at high 
Table 4 (continued). Changes in secondary lipid variables and high sensitivity C-reactive protein (hs-CRP) from baseline 
(start of the core study) to the start of the extension study (week 0) and from baseline to week 44 of the extension study in 
patients treated with pitavastatin or simvastatin. 
Parameter Change from baseline (mean±SD)
  Pitavastatin 4 mg (n=120) Simvastatin 40-80 mg (n=57)
Apo-B:Apo-A1 ratio  
 Baseline mean  0.98±0.2 1.00±0.2
 Baseline to extension week 0 (%) −0.4±0.2 −0.4±0.2
 Baseline to extension week 44 (%) −0.4±0.3 −0.4±0.2
Oxidized LDL  
 Baseline mean (U/L) 79.8±16.5 82.4±18.5
 Baseline to extension week 0 (U/L) −26.6±14.3 −29.4±17.5
 Baseline to extension week 44 (U/L) −30.0±16.4 −28.9±19.1
hs-CRP   
 Baseline mean (mg/L) 3.5±5.9 4.1±10.5
 Baseline to extension week 0 (mg/L) −0.7±6.8 0.4±5.4
 Baseline to extension week 44 (mg/L) −0.4±6.8 −1.8±10.8
Apo-A1=apolipoprotein A1; Apo-B=apolipoprotein B; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-
density lipoprotein cholesterol.
Table 5. Summary of treatment-emergent adverse events 
(TEAE) during treatment with pitavastatin or simvastatin.
TEAE Number (%) of patients 
  with a TEAE
  Pitavastatin Simvastatin 
  4 mg 40-80 mg 
  (n=121) (n=57)
Any TEAE 92 (76.0) 45 (78.9)
Serious TEAE 4 (3.3) 7 (12.3)
Treatment-related TEAE 13 (10.7) 10 (17.5)
Discontinuations due to TEAE 7 (5.8) 6 (10.5)
TEAE occurring in ≥2% of patients in either group 
 Headache 2 (1.7) 5 (8.8)
 Nasopharyngitis 24 (19.8) 15 (26.3)
 Constipation 4 (3.3) 2 (3.5)
 Myalgia 5 (4.1) 7 (12.3)
 Back pain 10 (8.3) 3 (5.3)
 Influenza 7 (5.8) 3 (5.3)
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risk of CHD. In the initial 12-week core 
study,14 pitavastatin 4 mg was shown to be 
statistically non-inferior to simvastatin 40 mg 
in lowering LDL-C concentrations, and more 
than 80% of patients reached the LDL-C targets 
recommended in the NCEP and EAS guidelines. 
By the end of the extension study, LDL-C target 
attainment rates in pitavastatin-treated patients 
remained above 80%, compared with 74%-75% 
in simvastatin-treated patients. Similar results 
were seen when the proportions of patients 
achieving the more stringent NCEP step 9 targets 
were analyzed. Taken together, the results of the 
core and extension studies therefore show that 
pitavastatin provides effective control of LDL-C 
concentrations in dyslipidemic patients. The 
finding in the core study14 that pitavastatin 
is non-inferior to simvastatin in this respect 
is important because LDL-C concentration 
is a recognized risk factor for atherosclerotic 
cardiovascular disease,17 and major outcome 
trials have shown that simvastatin significantly 
reduces cardiovascular mortality and morbidity 
in at-risk patients.18,19 Further studies to assess 
morbidity and mortality are currently underway 
in Japan to determine the long-term efficacy and 
safety of pitavastatin.
In addition to lowering LDL-C concentrations, 
pitavastatin treatment exerted beneficial effects 
on the broader lipid profile by increasing 
HDL-C and Apo-A1 levels and reducing levels 
of triglycerides, Apo-B, and oxidized LDL. 
The marked increase from baseline in HDL-C 
concentrations provided by pitavastatin after
12 weeks of treatment in the core study continued 
during the extension study, such that a larger 
increase was observed after 44 weeks (14.1% vs. 
9.3% at extension study baseline). These results 
are consistent with previous studies, which have 
shown that pitavastatin provides progressive, 
large increases in HDL-C concentrations during 
long-term treatment.12 The clinical relevance of 
changes in HDL-C concentrations during statin 
treatment is highlighted by a sub-analysis from 
the Scandinavian Simvastatin Survival Study 
(4S), in which simvastatin produced significantly 
greater reductions in cardiovascular mortality 
and morbidity in patients with the lowest 
HDL-C and highest triglyceride levels compared 
with patients with the highest HDL-C and the 
lowest triglyceride levels.20
Both treatments were well tolerated, but 
this extension study raises the prospect that 
pitavastatin may exhibit a more favorable long-
term tolerability profile than simvastatin. For 
example, pitavastatin was associated with a 
lower rate of TEAE considered to be related to 
study treatment (10.7% vs. 17.5% of patients on 
simvastatin), a lower rate of discontinuations due 
to TEAE (5.8% vs. 10.5% with simvastatin), and a 
lower incidence of myalgia (4.1% vs. 12.3% with 
simvastatin). These differences do not reflect 
the use of a higher dose of simvastatin (80 mg), 
which has been reported to be associated with 
an increased risk of myopathy;21,22 among the 
five patients who were titrated to simvastatin 
80 mg at the start of the extension study, none 
discontinued treatment due to a TEAE and only 
one patient reported myalgia. The low risk of 
muscular adverse events, such as myalgia and 
liver enzyme elevations, observed during long-
term pitavastatin treatment in the present study 
is consistent with previous trials that have 
shown a favorable safety and tolerability profile 
of pitavastatin in a broad range of patients.9-12 
The limitations of this study should be 
noted. The protocol was developed primarily 
to compare pitavastatin 4 mg with simvastatin 
40 mg (the most commonly prescribed statin 
regimen), and the effects of simvastatin 80 mg 
daily were evaluated in only a limited number 
of patients. The patient population for the 
extension study was entirely White, and so 
caution should be exercised in extrapolating the 
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results to other races or ethnic groups (eg, Black 
subjects) who were not represented. Finally, 
although pitavastatin was shown to provide 
similar lipid-modifying efficacy to simvastatin, 
the results of ongoing large-scale studies with 
sufficient statistical power to evaluate effects on 
“hard” clinical endpoints are required to confirm 
the benefits of pitavastatin on clinical outcomes.
CONCLUSION
In conclusion, this study has shown that long-
term treatment with pitavastatin 4 mg provides 
LDL-C concentration-lowering efficacy similar 
to simvastatin 40-80 mg. More than 80% of 
pitavastatin-treated patients reached the NCEP 
and EAS targets for LDL-C concentrations, and 
a similar proportion reached the NCEP targets 
for non-HDL-C concentrations. Further studies 
are required to ascertain whether the numerical 
trends suggesting that pitavastatin may exhibit 
a more favorable long-term tolerability profile 
than simvastatin, indicated particularly by 
the lower incidence of study discontinuations 
due to TEAE and a lower rate of myalgia, are 
statistically significant. These findings suggest 
that pitavastatin is an effective option for the 
management of dyslipidemia in patients at high 
cardiovascular risk.
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